Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years
This study demonstrates that improvements with IVT-AFL 2 mg were maintained through month 36, suggesting that long-term durability of vision is achievable in patients with treatment-naïve nAMD in real-world practice. .
Authors
- Paul Mitchell (ORCID: https://orcid.org/0000-0003-2470-3790)
- Clare Bailey (ORCID: https://orcid.org/0000-0003-2141-4512)
- Tobias Machewitz
- Helmut Allmeier (ORCID: https://orcid.org/0000-0002-5165-4851)
- Se Woong Kang (ORCID: https://orcid.org/0000-0001-8755-3465)
- Varun Chaudhary (ORCID: https://orcid.org/0000-0002-9988-4146)
- JinKyung Lee
- Jean‐François Korobelnik (ORCID: https://orcid.org/0000-0002-4438-9535)
- Xin Zhang (ORCID: https://orcid.org/0000-0001-5555-0825)
Institutions
- The University of Sydney (AU)
- Université de Bordeaux (FR)
- Inserm (FR)
- Samsung Medical Center (KR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bordeaux Population Health (FR)
- Bristol Eye Hospital (GB)
- Bayer (Switzerland) (CH)
- Westmead Institute for Medical Research (AU)
- St. Joseph’s Healthcare Hamilton (CA)
- Bayer (Germany) (DE)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Ophthalmologica
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1159/000549663
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer